KidNEYCAnCeR

Articles by KidNEYCAnCeR October 15, 2026

AROUND THE CORNER:Top Developments in Genitourinary Cancer Therapeutics

The third quarter of 2026 was defined less by new readouts than by regulatory follow-through. Data from ASCO GU and the ASCO Annual Meeting turned into FDA approvals in muscle-invasive bladder cancer and metastatic hormone-sensitive prostate cancer, and biomarker-selected strategies moved firmly…

107Views 0Comments

JOURNAL CLUB

Journal Club selections are curated by the Kidney Cancer Journal editorial team based on clinical significance, study design rigor, and potential impact on practice. Full-text access available via PubMed and respective journal platforms. Belzutifan plus lenvatinib versus cabozantinib in patients with previously…

Articles by KidNEYCAnCeR October 10, 2026

261Views 0Comments

ESMO 2026 SNEAK PEEK

█ For kidney cancer, ESMO 2026 has one of its most concentrated programmes in years. Nearly all of the practice-relevant renal data come on a single day, Sunday, October 25. The morning Proffered Paper session puts both phase 3 belzutifan readouts, a…

Articles by KidNEYCAnCeR October 10, 2026

228Views 0Comments

Multi-omics Approaches Identify Uremic Toxins and Immune Regulators as Circulating Biomarkers of Metastatic RCC

Moshe C. Ornstein1,#, Xiayan Ye2,3, Sumita Dutta2,3, Venkateshwari Varadharajan2,3, Wei Wei4, Marcelo Lamenza1, Monaben Patel5, C. Marcela Diaz-Montero5, J. Mark Brown2,3,6,#, and Abhishek A. Chakraborty5,6,#Ϯ ABSTRACT BACKGROUND: The diagnosis and treatment of metastatic renal cell carcinoma (mRCC) is challenging. Drug combinations targeting…

Latest Issue Latest Updates by KidNEYCAnCeR October 10, 2026

184Views 0Comments

Stereotactic Body Radiotherapy for Primary Renal Tumors: Technological Evolution, Current Evidence and Practical Recommendations

1. Introduction and Background Renal cell carcinoma (RCC) is frequently detected incidentally on imaging tests performed for other reasons, and its incidence continues to increase, particularly in the elderly (1). Although surgical resection of the tumor remains the treatment of choice…

Editor's Memo Latest Updates by KidNEYCAnCeR October 10, 2026

145Views 0Comments

The Adjuvant Reckoning: Belzutifan,Toxicity, and the Next Phase of RCC Care

Thomas E. Hutson, DO, PharmD Editor-in-Chief. Dear Colleagues, This has been an unusually productive stretch for renal cell carcinoma (RCC) research, and the Third Quarter 2026 issue of Kidney Cancer Journal reflects that momentum. Between the follow-through from ASCO's Genitourinary…

Articles by KidNEYCAnCeR July 1, 2026

740Views 0Comments

EXPERT COMMENTARY – ASCO26

Perspectives synthesized from ASCO 2026 presenter and discussant sessions and post-meeting expert commentary. Prepared for educational purposes by the Kidney Cancer Journal editorial team. Toni K. Choueiri, MD, FASCO. Dana-Farber Cancer Institute, Boston, MA. Presenter — LITESPARK-022 and KEYNOTE-564 ctDNA Analysis…

Latest Updates by KidNEYCAnCeR June 17, 2026

657Views 0Comments

Management of Carcinoid Tumor within a Horseshoe Kidney

Andrea Lopez Sanmiguel1, Dilara Akbulut1, Jeff Chen1, Yash S. Khandwala1, Paul Russo1† Affiliations: 1 Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY Abstract Horseshoe kidney is the most common renal fusion…

Articles by KidNEYCAnCeR June 17, 2026

3212Views 0Comments

ASCO 2026 Annual Meeting: Kidney Cancer: Clinical and Research Highlights

doi.org/10.52733/ASCO26Summary Thomas E. Hutson, DO, PharmD, FACP Editor-in-Chief, Kidney Cancer Journal A Summary Report for the Global Oncology Community Chicago, Illinois | May 29 – June 2, 2026 | Kidney Cancer Journal, Volume 24…

2026 ASCO Latest Updates by KidNEYCAnCeR June 17, 2026

3179Views 0Comments

The Architecture of a Cure: Where Renal Cell Carcinoma Research Stands in 2026

Thomas E. Hutson, DO, PharmD, FACP EDITORIAL NOTE | Editor-in-Chief, Kidney Cancer Journal There is a particular kind of optimism that belongs only to a field in the midst of genuine transformation…

Author page: KidNEYCAnCeR

AROUND THE CORNER:Top Developments in Genitourinary Cancer Therapeutics

JOURNAL CLUB

ESMO 2026 SNEAK PEEK

Multi-omics Approaches Identify Uremic Toxins and Immune Regulators as Circulating Biomarkers of Metastatic RCC

Stereotactic Body Radiotherapy for Primary Renal Tumors: Technological Evolution, Current Evidence and Practical Recommendations

The Adjuvant Reckoning: Belzutifan,Toxicity, and the Next Phase of RCC Care

EXPERT COMMENTARY – ASCO26

Management of Carcinoid Tumor within a Horseshoe Kidney

ASCO 2026 Annual Meeting: Kidney Cancer: Clinical and Research Highlights

The Architecture of a Cure: Where Renal Cell Carcinoma Research Stands in 2026

About Us

Contents

Follow Us

Guidelines

Patient Resources